The following antibodies were used:
anti-MYCN,
anti-p53, anti-Actin (B8.4.B, FL-393 and I-19, respectively, Santa Cruz Biotechnology), anti-MYC (Y69, OriGene), and anti-MDM2 (2A10, Calbiochem-Millipore) for western blotting; anti-CD107a-FITC (H4A3), anti-CD3-Alexa-700 (UCHT1), anti-CD56-PE-Cy7 (B159), anti-CD45 (HI30), FITC-conjugated rat anti-mouse IgG1 (A85–1) and PE-conjugated rat anti-mouse IgM (R6–60.2) purchased from BD Biosciences;
anti-ULBP1-PE (170818), anti-ULBP2/5/6-PE (165903), anti-ULBP3-PE (166510),
anti-MICA (159227), anti-MICB (236511),
anti-TRAIL/R2-APC (17908),
anti-CD155/PVR-PE (300907),
anti-Nectin-2/CD112-APC (610603) purchased from R&D Systems; W6/32 which recognizes human fully-assembled MHC class I heavy chains and goat F(ab’)2 Fragment anti-mouse IgG FITC (IM1619, Dako) for flow cytometry;
anti-MICA and anti-Nectin-2 (62540 and 154895, respectively, Abcam) for immunohistochemistry assay.
Whole-cell extracts were quantified by the
bicinchoninic acid assay (Thermo Fisher Scientific), resolved on 8–10% SDS-PAGE and electroblotted. Filters were probed with primary antibodies followed by
goat anti-mouse IgG HRP conjugated (Jackson). Flow cytometry was performed on
FACSCantoII (BD Bioscences) and analyzed by FlowJo Software.
Brandetti E., Veneziani I., Melaiu O., Pezzolo A., Castellano A., Boldrini R., Ferretti E., Fruci D., Moretta L., Pistoia V., Locatelli F, & Cifaldi L. (2017). MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma. Oncoimmunology, 6(6), e1316439.